No title
The dominant narrative on equity, diversity, and inclusion in U.S. medical research emphasises the underrepresentation of Black and Hispanic participants in clinical trials, largely based on therapeutic phase 2 and 3 trials. Far less attention has been paid to phase 1 trials—particularly those involving healthy volunteers who assume health risks without therapeutic benefit, often for money. Focusi
